Here's why Goldman Sachs is warning of more selling for stocks this week - MarketWatch# Here's why Goldman Sachs is warning of more selling for stocks this week## CTAs are ready to sell over the next week, no matter what stocks doPublished: Feb. 9, 2026 at 6:11 a.m. ETShareResize---Listen(4 min)Goldman analysts say brace for more selling over the next month. Photo: Getty ImagesInvestors may not have seen the end of last week's market volatility, with some big automated funds waiting in the wings to push the ...

Group 1: Market Overview - The stock market has become more volatile recently, raising concerns about a potential bubble in AI stocks [1] - Uncertainty surrounding the Federal Reserve's actions and changing U.S. trade policies may lead some investors to be cautious [1] Group 2: Realty Income - Realty Income (NYSE: O) is the sixth-largest real estate investment trust (REIT) globally, owning over 15,500 properties across the U.S. and eight other countries [5] - The company boasts a forward dividend yield exceeding 5.1% and has increased its dividend for 30 consecutive years and 112 consecutive quarters [5][6] - Realty Income has demonstrated stable growth across various macroeconomic conditions, consistently outperforming the S&P 500 with lower volatility [6] - The company sees significant growth potential in Europe, with a total addressable market of $8.5 trillion, and is expanding into private capital [7] Group 3: United Parcel Service - United Parcel Service (NYSE: UPS) is a major package delivery company operating a large fleet and delivering packages in over 200 countries [8] - UPS has maintained its dividend since going public in 1999, with a forward dividend yield of 5.6% [8] - The company expects to generate approximately $6.5 billion in free cash flow this year while paying around $5.4 billion in dividends, allowing for capital expenditures of about $3 billion [9]

As Monday, February 9th, 2026, unfolds, the U.S. stock market is poised for a dynamic session, with premarket trading indicating a cautiously optimistic start following a robust close to the previous week. Investors are closely monitoring futures movements, upcoming economic reports, and a flurry of corporate news, particularly from the technology sector. The recent surge in major indexes, including the Dow Jones Industrial Average, has set an intriguing backdrop for the week ahead.Premarket Activity and Fu ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

China's Nio is recalling 246,229 vehicles due to a software issue that poses safety hazards, marking the largest recall by a homegrown electric vehicle maker. ...

AIG has completed the acquisitions of strategic minority ownership stakes in specialty insurer and reinsurer Convex Group and global asset manager Onex Corporation.Following regulatory approvals AIG now owns an approximately 35% equity interest in Convex (worth approximately $2.1bn or £1.54bn), and a 9.9% ownership stake in Onex (worth approximately $642m or £472m).In conjunction with AIG’s investment in Convex, founding investor Onex has become the majority shareholder in Convex with a 63% ownership intere ...

Core Insights - Gencom has acquired the 253-room Ritz-Carlton New York, Central Park hotel, marking its third luxury hotel acquisition in New York City within 16 months [1][2] - The acquisition is financed by Banco Inbursa and represents Gencom's 11th collaboration with The Ritz-Carlton brand [1][2] - The hotel features a gastro lounge, spa, and a newly renovated fitness center, with guest rooms designed for luxury and comfort [2][3] Company Strategy - Gencom aims to strengthen its presence in New York City, viewing it as a market with compelling long-term opportunities for luxury assets [2] - The acquisition aligns with Gencom's investment strategy focused on excellence, as stated by the chief investment officer [3] - The Ritz-Carlton New York, Central Park will be integrated into Gencom's hospitality portfolio, which includes other luxury brands [3]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to avoid access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Core Insights - SanDisk's stock has surged by 1,561% over the past year, primarily due to severe shortages of high-bandwidth memory (HBM) essential for AI infrastructure [1] - The company's Q2 2026 revenues reached $3 billion, marking a 61% year-over-year increase, with earnings per share rising to $6.20, a fivefold increase [1] - HBM supply shortages are projected to persist until at least 2028, significantly impacting prices and availability of various electronic devices [1] Financial Performance - SanDisk's Q2 2026 revenues were reported at over $3 billion, a 61% increase compared to the previous year [1] - Earnings per share for Q2 2026 were $6.20, reflecting a fivefold increase from prior periods [1] - Q3 guidance anticipates revenues of $4.6 billion, representing a 172% year-over-year gain, with projected earnings per share of $13 [1] Market Dynamics - The demand for HBM chips, driven by AI data centers, is expected to outstrip supply for the next decade, leading to increased prices for consumer electronics [1] - A specific example of price escalation is noted with Crucial Pro's 64GB DDR5 RAM kit, which rose from $145 in October 2025 to $790 in February 2026 [1] - The ratio of memory chips in overall materials costs for manufacturers has increased from 15% to approximately 40% [1] Valuation Insights - Analysts suggest that at SanDisk's current earnings rate, a 26x earnings multiple would value the stock at over $1,900 per share, indicating significant upside potential [1] - SanDisk is positioned as a more stable investment in the AI sector compared to pure AI stocks, due to its involvement in HBM production [1]

Core Viewpoint - MannKind Corporation has initiated the INHALE-1 clinical study to evaluate the safety and efficacy of Afrezza inhaled insulin in youth aged 10 to under 18 years recently diagnosed with type 1 diabetes, aiming to reduce the burden of insulin injections for pediatric patients and their families [1][2]. Group 1: Study Details - The INHALE-1 study will assess Afrezza used in combination with subcutaneously injected basal insulin once daily, focusing on clinical outcomes and participant satisfaction [2]. - The study will enroll approximately 100 patients across about 10 clinical sites in the United States, with the first patient enrolled at the Barbara Davis Center for Diabetes in Aurora, Colorado [3]. - Participants will be followed for 13 weeks during the main phase, with an optional extension phase for up to 26 weeks [4]. Group 2: Primary Endpoint and Objectives - The primary endpoint is the percentage of participants with a Continuous Glucose Meter (CGM) measuring time in range (TIR) of 70-180 mg/dL at least 70% during the 14 days prior to the 13-week visit [4]. - The study aims to evaluate whether replacing most insulin injections with inhalations can ease the adjustment to managing type 1 diabetes for children and their families [2]. Group 3: Regulatory Status - The FDA is currently reviewing a supplemental Biologics License Application (sBLA) for Afrezza in children and adolescents with type 1 or type 2 diabetes, with a target action date of May 29, 2026 [5]. - If approved, Afrezza would be the first needle-free insulin option for pediatric patients in over a century [5]. Group 4: Company Overview - MannKind Corporation is focused on transforming chronic disease care through innovative solutions, particularly in cardiometabolic and orphan lung diseases [9][10]. - The company aims to develop treatments that address serious unmet medical needs, including diabetes and related conditions [9].